You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
萬方發展(000638.SZ):控股子公司與杭州生物擬開展疫苗研發和重組蛋白藥物CRO服務等工作
格隆匯 12-25 19:47

格隆匯 12 月 25日丨萬方發展(000638.SZ)公佈,公司控股子公司吉林萬方百奧生物科技有限公司(萬方百奧)20201224杭州生物醫藥創新研究中心(杭州生物)簽訂杭州生物醫藥創新研究中心萬方百奧成立中國mRNA疫苗研究院戰略合作備忘錄》根據備忘錄約定雙方擬在温州成立合資公司,依託杭州生物的技術團隊,結合萬方百奧疫苗行業的資深專家及技術開發力量,開展疫苗研發和重組蛋白藥物CRO服務等工作

雙方本着“協同創新、優勢互補、共同發展、互惠互利”的原則,經友好協商,達成戰略性合作意向:mRNA疫苗研發,預防性生物製品和重組蛋白藥物研發平台,mRNA重組蛋白疫苗基因工程疫苗的CDMO生產

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account